Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) Equity Average (2018 - 2025)

Historic Equity Average for Autolus Therapeutics (AUTL) over the last 6 years, with Q3 2025 value amounting to $306.0 million.

  • Autolus Therapeutics' Equity Average fell 3910.13% to $306.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $306.0 million, marking a year-over-year decrease of 3910.13%. This contributed to the annual value of $269.4 million for FY2024, which is 3136.7% up from last year.
  • Autolus Therapeutics' Equity Average amounted to $306.0 million in Q3 2025, which was down 3910.13% from $358.8 million recorded in Q2 2025.
  • Autolus Therapeutics' Equity Average's 5-year high stood at $554.9 million during Q2 2024, with a 5-year trough of $146.0 million in Q4 2023.
  • For the 4-year period, Autolus Therapeutics' Equity Average averaged around $317.0 million, with its median value being $292.2 million (2022).
  • As far as peak fluctuations go, Autolus Therapeutics' Equity Average soared by 20969.68% in 2024, and later crashed by 3910.13% in 2025.
  • Quarter analysis of 4 years shows Autolus Therapeutics' Equity Average stood at $229.9 million in 2022, then tumbled by 36.5% to $146.0 million in 2023, then surged by 209.7% to $452.1 million in 2024, then crashed by 32.33% to $306.0 million in 2025.
  • Its Equity Average stands at $306.0 million for Q3 2025, versus $358.8 million for Q2 2025 and $399.2 million for Q1 2025.